# CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Source: https://onco.cc/trials/nct05143996/  
OnCo record `nct05143996` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CLN-049 run by Cullinan Therapeutics Inc., now recruiting.

## Summary

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) is a phase 1/2 interventional study registered as NCT05143996 by Cullinan Therapeutics Inc., with 275 participants planned, started 2021-11-18. Conditions recorded: Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and TP53-mutated MDS and AML. Interventions recorded: CLN-049.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05143996
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Sponsor: Cullinan Therapeutics Inc.
- Enrolled: 275

## Sources

- ClinicalTrials.gov NCT05143996: https://clinicaltrials.gov/study/NCT05143996

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [CLN-049](https://onco.cc/drugs/cln-049/)
- companies: [Cullinan Therapeutics](https://onco.cc/companies/cullinan-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05143996.json